Pfizer ($PFE) has locked in another agreement to stave off generic competition to Detrol LA, its drug for people with overactive bladders. Reuters says Pfizer and Mylan ($MYL) have reached an agreement on the Pfizer lawsuit that Mylan infringed its patent. Under the deal, which it says must be vetted by the Federal Trade Commission, Mylan will begin making a generic version from Jan. 1, 2014, or possibly earlier, but no later than March 1, 2014. Pfizer and Impax Laboratories ($IPXL) last month reached an undisclosed accommodation on if and when Impax will be able to launch a generic of Detrol LA. Detrol and the extended-release version racked up more than $880 million last year. Scrutiny of how patent holders and generics companies work out their differences, a long-simmering issue, heated up again two weeks ago when the FTC intervened in a lawsuit against Pfizer and Teva Pharmaceutical Industries ($TEVA) over their arrangement for handling the launch of a generic of Effexor XR, a blockbuster antidepressant. A group of drugstores sued the companies, alleging that they colluded to stop the launch. Story | More